Prospective evaluation of FibroTest®, FibroMeter®, and HepaScore® for staging liver fibrosis in chronic hepatitis B: Comparison with hepatitis C

Leroy, Vincent; Stürm, Nathalie; Faure, Patrice; Trocmé, Candice; Marlu, Alice; Hilleret, Marie‐Noëlle; Morel, Françoise; Zarski, Jean–Pierre

doi:10.1016/j.jhep.2014.02.029

Cited by 67 publications

(41 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In 78 HBV patients, Wu and colleagues found that the Fibrometer test performed well in 78 HBV patients, diagnosing significant and severe fibrosis with AUROC values of 0.85 and 0.94, respectively (89). Another study showed that although Fibrometer showed good diagnostic accuracy in HBV, it tended to underestimate significant fibrosis when compared with HCV (90). Hepascore ® is a patented test that consists of age, gender, HA, bilirubin, gamma-glutamyl-transpeptidase (γGT), and α2-marcoglobulin.…”

Section: Direct Serum Markers Of Fibrosismentioning

confidence: 99%

Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection

Parikh¹,

Ryan²,

Tsochatzis³

2017

Ann. Transl. Med.

View full text Add to dashboard Cite

Chronic hepatitis B virus (HBV) infection is a major cause of liver morbidity and mortality worldwide.While a proportion of the 250 million individuals chronically infected with HBV will not come to significant harm or require therapy, many others risk developing complications of the end-stage liver disease such as decompensated cirrhosis and hepatocellular carcinoma (HCC), without intervention. Due to the complex natural history of HBV infection, patients require an expert assessment to interpret biochemistry, viral serology and appropriately stage the disease, and to initiate monitoring and/or therapy where indicated. The detection and quantification of liver fibrosis is a key factor for disease management and prognostication for an individual with HBV. The reliance on invasive liver biopsy to stage disease is diminishing with the advent of robust non-invasive blood-and imagingbased algorithms which can reliably stage disease in many cases. These tests are now incorporated into International guidelines for HBV management and relied upon daily to inform clinical judgement. Both blood-and imagingbased approaches have advantages over liver biopsy, including minimal risks, lower cost, better patient acceptance and speed of results, while disadvantages include lower diagnostic accuracy in intermediate disease stages and variability with co-existing hepatic inflammation or steatosis. This review outlines the methods of fibrosis assessment in chronic HBV infection and focuses on the most commonly used blood-and imaging-based noninvasive tests, reviewing their diagnostic performance and applicability to patient care.

show abstract

Section: Direct Serum Markers Of Fibrosismentioning

confidence: 99%

Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection

Parikh¹,

Ryan²,

Tsochatzis³

2017

Ann. Transl. Med.

View full text Add to dashboard Cite

show abstract

“…Leroy et al[24] compared the overall diagnostic performances of serum markers of liver fibrosis (FibroTest ® , FibroMeter ® , and HepaScore ® ) in 510 HBV or HCV monoinfected patients and found that these were similar between HBV and HCV, with the area under the receiver operating characteristic (AUROC) curve ranging from 0.82 to 0.85 for advanced fibrosis and 0.84 to 0.87 for cirrhosis, respectively[24]. …”

Section: Emerging Non-invasive Assessment Of Extensive Fibrosis or CImentioning

confidence: 99%

Evolving strategies for liver fibrosis staging: The non-invasive assessment

Stasi

Milani

2017

WJG

View full text Add to dashboard Cite

Transient elastography and the acoustic radiation force impulse techniques may play a pivotal role in the study of liver fibrosis. Some studies have shown that elastography can detect both the progression and regression of fibrosis. Similarly, research results have been analysed and direct and indirect serum markers of hepatic fibrosis have shown high diagnostic accuracy for advanced fibrosis/cirrhosis. The prognosis of different stages of cirrhosis is well established and various staging systems have been proposed, largely based on clinical data. However, it is still unknown if either non-invasive markers of liver fibrosis or elastography may contribute to a more accurate staging of liver cirrhosis, in terms of prognosis and fibrosis regression after effective therapy. In fact, not enough studies have shown both the fibrosis regression in different cirrhosis stages and the point beyond which the prognosis does not change - even in the event of fibrosis regression. Therefore, future studies are needed to validate non-invasive methods in predicting the different phases of liver cirrhosis.

show abstract

“…Guidance for assessing liver fibrosis with HCV infections is available (71,72). Regarding hepatic decompensation, once is cirrhosis is established, patients have a 3À6% annual risk of hepatic decompensation (variceal hemorrhage, ascites, encephalopathy).…”

Section: Endpoints In Clinical Trials Against Hcvmentioning

confidence: 99%

Endpoints for Infections

Brody¹

2016

Clinical Trials

View full text Add to dashboard Cite

Prospective evaluation of FibroTest®, FibroMeter®, and HepaScore® for staging liver fibrosis in chronic hepatitis B: Comparison with hepatitis C

Cited by 67 publications

References 29 publications

Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection

Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection

Evolving strategies for liver fibrosis staging: The non-invasive assessment

Endpoints for Infections

Contact Info

Product

Resources

About